Side-by-side · Research reference
SurvodutidevsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED25/54 cited
BPhase 2HUMAN-REVIEWED8/46 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
Survodutide
TB-500
Primary target
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
—
Endogenous protein at baseline; supplementation amplifies
Antibody development
—
—
02Dosage Protocols
Parameter
Survodutide
TB-500
Standard dose
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Once weekly
2× per week (loading); then 1× per week (maintenance)
Evidence basis
Phase 2 RCT (obesity) · Phase 3 ongoing
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Lower / starter dose
—
1 mg per injection
Duration
—
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
—
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
—
Evening or pre-rest preferred (anecdotal)
Half-life
—
~2 hours (estimated; tissue uptake longer)
03Metabolic / Fat Loss Evidence
Parameter
Survodutide
TB-500
Primary fat target
Total body weight, visceral adipose tissue
—
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
—
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
—
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
—
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
—
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class
—
04Side Effects & Safety
Parameter
Survodutide
TB-500
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Rare nausea (anecdotal)
Safety profile
Network meta-analysis: comparable safety to other GRAs
—
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
—
Injection site reactions
Expected with subcutaneous administration
—
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
—
Injection site reaction
—
Mild erythema, transient pain
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Pregnancy / OB
—
Avoid
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
Survodutide
TB-500
1. Reconstitution
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
Survodutide
— no documented stacks
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair